Competitive Intensity Grows in Alzheimer's Disease Drug Development Race
"There were many controversies emerging from ICAD, and as one wouldexpect, we have heard the perspectives of thought leaders on both sides of theissues," according to MedPredict President Dr. Jeffrey Berk. "In this report,our panelists provide cogent arguments supporting their opinions andpredictions, pro and con, for the pharmacotherapies and diagnostics in theAlzheimer's disease pipeline."
The report provides detailed tables from the key presentations at ICAD, aswell as discussion of key compounds in development, includingacetylcholinesterase inhibitors, NMDA, serotonin (5HT), alpha-7 nicotinicacetylcholine agonists, active and passive immunotherapy, gamma-secretase andbeta-secretase inhibitors, insulin related mechanisms (IDE, RAGE),mitochondrial stabilization, metal chelation, and more.
Companies included in this report: Abbott, AC Immune/Genentech, Affiris,Allon, Astellas/CoMentis, AstraZeneca/Targacept, Avid, Baxter, Bayer ScheringPharma/Avid Radiopharmaceuticals, Boehringer-Ingelheim/Ablynx, Bristol-MyersSquibb, Elan, Elan/Transition Therapeutics/AstraZeneca, Elan/Wyeth, C2NDiagnostics, Forest/Merz/Lundbeck/Daiichi Sankyo, GE Healthcare,GlaxoSmithKline, GlaxoSmithKline/Epix, Intellect Neurosciences/Elan/Wyeth,Kurve Technology, Lilly, Lilly/Elan, Memory Pharmaceuticals, Merck, Myriad,Novartis, Pfizer, Pfizer/Medivation, Pfizer/TransTec, Prana, Roche/Memory,Roche/Morphosys, Siemens, Suven, TauRx, U Pittsburgh, Wellstat, and Wyeth.
The full report may be purchased by contacting MedPredict.
MedPredict (http://www.medpredict.com) maintains a proprietary database ofover 1,000 global physician thought leaders. Based on primary interviews withthese thought leaders, MedPredict publishes periodic therapeutic area reportsto keep clients up-to-date on emerging trends and competitive activity. Thereports include thought leader reactions to recent publications andpresentations, as well as clinical, regulatory and marketing activity.The report addresses the following questions: -- Which company has the best position in Alzheimer's, from the thought leaders' perspective? -- How should Elan/Wyeth's data on bapineuzumab data be interpreted, and what are the implications? -- What will be the initial role of imaging and biomarkers in Alzheimer's? -- Is the hype around TauRx's Rember and Pfizer's/Medivation's Dimebon supported by the data?
You May Also Like